title: Metastatic bone pain: treatment options with an emphasis on bisphosphonates.
abstract: BACKGROUND
  One of the key targets for metastatic cancer cells is the skeleton. Once metastatic cells are established within the bone matrix, skeletal integrity becomes increasingly compromised. Bone lesions lead to various complications, including bone pain, fractures and spinal cord compression.
  Bone pain is debilitating and affects quality of life of the patient. In addition, it increases the use of health care resources. Many patients with metastatic bone disease experience substantial bone pain despite state-of-the-art systemic analgesic treatment. Incident pain is the predominant pain syndrome.
  Typically, this syndrome requires moderate baseline analgesia with increased on-demand doses. Other techniques for treating bone pain, including radiation therapy, neuraxial application of analgesics, nerve blocks and local stabilisation procedures, should be considered. In addition, therapy with bisphosphonates targeting bone-specific pain is an important strategy. This review discusses the various management options for bone pain arising from metastatic bone disease.
authors.affiliation: Medical Oncology, Kantonsspital Graubünden, Loestrasse 170, Chur, 7000, Switzerland. roger.vonmoos@ksgr.ch
authors.forename: Roger
authors.initials: R
authors.lastname: von Moos
authors.forename: Florian
authors.initials: F
authors.lastname: Strasser
authors.forename: Silke
authors.initials: S
authors.lastname: Gillessen
authors.forename: Kathrin
authors.initials: K
authors.lastname: Zaugg
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000503:physiopathology* / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D010148:Intractable Pain / Q000188:drug therapy*; D010166:Palliative Care; D011788:Quality of Life
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates